Brodalumab as a Second-Line Therapy in Psoriasis: Rapid Response and Unique Mechanism of Action After Biologic Failure

By afschroeder • September 20, 2025

Green L, Armstrong A, Han G, Jacobson A. Brodalumab as a Second-Line Therapy in Psoriasis: Rapid Response and Unique Mechanism of Action After Biologic Failure. Dermatol Ther (Heidelb). 2025 Sep 19. doi: 10.1007/s13555-025-01533-9. Epub ahead of print. PMID: 40971026.

Tags: Biologic failure, Dermatology, ixekizumab, Publications, Quality of Life, Refractory, secukinumab, Therapy switching, tnf inhibitor

Related Posts

Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis

Silverberg JI, Bieber T, Eyerich K, Armstrong AW, Nickoloff BJ, Natalie CR, Gallo G, Okragly A, Wolf E, Xu C, Moser BA, Rueda MJ, Elmaraghy[...]

The liver regulates ectopic calcification in Abcc6-deficient models of Pseudoxanthoma Elasticum

Wang Y, Sun B, Ma F, Tao B, Gu Y, Zhou Z, Kim J, Zhang L, Liu Z, Ten Hoeve J, Stiles L, Fernandez-Del-Rio L,[...]

GLP-1RAs and cardiovascular risk reduction in psoriasis: A retrospective cohort study

Ma EJ, Roberts AM, Jeong CY, Chou P, Katz A, Nong Y, Johnsen N, Yan M, Ochoa MT, Armstrong AW. GLP-1RAs and cardiovascular risk reduction[...]